{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:43:51Z","timestamp":1770835431015,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40262-014-0173-y","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T07:28:23Z","timestamp":1411025303000},"page":"1137-1147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome"],"prefix":"10.1007","volume":"53","author":[{"given":"Yulan","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Musson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Schweighardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Jesaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Shaywitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"173_CR1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","volume":"110","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, Gravance CG, Orii T, Tomatsu S. Review of clinical presentation and diagnosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110:54\u201364.","journal-title":"Mol Genet Metab"},{"key":"173_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","volume":"101","author":"J Nelson","year":"1997","unstructured":"Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101:355\u20138.","journal-title":"Hum Genet"},{"key":"173_CR3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajmg.a.20314","volume":"123A","author":"J Nelson","year":"2003","unstructured":"Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A:310\u20133.","journal-title":"Am J Med Genet A"},{"key":"173_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, Guffon N, Burton BK, Hendriksz CJ, Mitchell J, Martins A, Jones S, Guelbert N, Vellodi A, Hollak C, Slasor P, Decker C. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54\u201361.","journal-title":"Mol Genet Metab"},{"key":"173_CR5","doi-asserted-by":"crossref","unstructured":"Hendriksz CJ, Burton BK, Fleming TR, Harmatz PR, Hughes D, Jones SA, Lin SP, Mengel E, Scarpa M, Valayannopoulos V, Giugliani R, STRIVE Investigators, Slasor P, Lounsbury D, Dummer W. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study, J Inherit Metab Dis. 2014. (Epub ahead of print).","DOI":"10.1007\/s10545-014-9715-6"},{"key":"173_CR6","doi-asserted-by":"crossref","first-page":"e12194","DOI":"10.1371\/journal.pone.0012194","volume":"5","author":"M Dvorak-Ewell","year":"2010","unstructured":"Dvorak-Ewell M, Wendt D, Hague C, Christianson T, Koppaka V, Crippen D, Kakkis E, Vellard M. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 2010;5:e12194.","journal-title":"PLoS One"},{"key":"173_CR7","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ymgme.2011.11.076","volume":"105","author":"C Hendriksz","year":"2012","unstructured":"Hendriksz C, Vellodi A, Jones S, Takkele H, Lee S, Chesler S, Decker C. Long term outcomes of a phase 1\/2, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and efficacy of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). Mol Genet Metab. 2012;105:S35.","journal-title":"Mol Genet Metab"},{"key":"173_CR8","unstructured":"Qi Y, Musson D, Martell L, Van Tuyl A, Decker C, Santos S, Garcia L, Lau K, Devereaux D, O\u2019Neill C. Phase 1\/2 pharmacokinetic studies of recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) in MPS IVA patients. In: Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14\u201317, 2012; Chicago. 2012; Poster T3338."},{"key":"173_CR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"173_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Monta\u00f1o","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"173_CR11","unstructured":"BioMarin Pharmaceutical. Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IV A (Morquio A syndrome). Briefing document for the endocrinologic and metabolic drugs advisory committee, FDA, http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM375127.pdf . 19 Nov 2013, p. 53."},{"key":"173_CR12","unstructured":"BioMarin Pharmaceutical. Naglazyme (galsulfase): highlights of prescribing information, Novato; 2013."},{"key":"173_CR13","unstructured":"BioMarin Pharmaceutical, Genzyme Corporation, Aldurazyme (laronidase): Highlights of prescribing information, Novato and Cambridge; 2013."},{"key":"173_CR14","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, Yu ZF, Swiedler SJ, Hopwood JJ, MPS VI Study Group. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681\u20139.","journal-title":"Pediatrics"},{"key":"173_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/prep.1994.1035","volume":"5","author":"ED Kakkis","year":"1994","unstructured":"Kakkis ED, Matynia A, Jonas AJ, Neufeld EF. Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells. Protein Expr Purif. 1994;5:225\u201332.","journal-title":"Protein Expr Purif."},{"key":"173_CR16","unstructured":"Shire Human Genetic Therapies, Elaprase (idursulfase): Highlights of prescribing information, Lexington; 2013."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0173-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0173-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0173-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:20Z","timestamp":1551204740000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0173-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["173"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0173-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}